The view from the hill...
May had something to do with the 23 million share dilution, lol...
On April 27, 2016, Gary L. Sender resigned as Chief Financial Officer of Synergy Pharmaceuticals Inc. (the “Company”) for personal reasons, effective April 30, 2016. Bernard F. Denoyer, who has served as Senior Vice President of Finance and Secretary at the Company since 2008, will assume responsibilities as Principal Financial Officer.
That's all folks..
Free markets at work!
hey hawk25702, how have you been? Your posts have indicated that you have been adding to your SGYP investment from 10 to 9 to 8 to 7 to 6 to 5 to 4 to 3 and now 2, all they way down. Have the courage to march on like any loyal long..
Review of Board Membership and Structure
As previously reported in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, the Company is currently conducting a company-wide, strategic review of the Company's operations aimed at increasing shareholder value. As part of this review, the Board has unanimously authorized Alexander J. Denner, Chairman of the Board, and Paris Panayiotopoulos, President, Chief Executive Officer and member of the Board, to evaluate the size, composition and organization of the Board, including whether to reconstitute the membership of the Board and/or to eliminate the classified board structure. In order to facilitate such evaluation and a potential reconstitution and/or declassification of the Board, each of the Company's directors tendered his or her conditional resignation from the Board (each, a "Conditional Resignation").
Each Conditional Resignation provides that if any director is not selected to serve on the reconstituted Board, such director will resign from the Board effective as of the Company's 2016 annual meeting of stockholders. Further, with respect to any Class 3 director with a term expiring at the Company's 2018 annual meeting of stockholders, each Conditional Resignation provides further that if the Board approves an amendment to the Company's certificate of incorporation to effect a declassification of the Board, which amendment is approved by the Company's stockholders at the 2016 annual meeting of stockholders, such director will resign from the Board effective as of the date immediately prior to the 2017 annual meeting of stockholders.
You can thank me later..
Lots of unknowns now in the economy..
Durable cytogenetic and molecular responses were observed irrespective of baseline mutation status, and included patients with compound mutations. No single or compound mutation was identified that consistently conferred primary and/or secondary resistance to ponatinib in CP-CML patients.
Expansion of a new business enterprise too rapidly causes many new companies to absolutely fail. It is all about business evolution.
KMI was structured for a stable or increasing NGAS market. This decline is not over.
Brokers and Investment bankers were all over themselves pumping this to the retail crowd..